Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense.

Public health assessment of potential biological terrorism agents. Emerg Infect Dis (2002) 8.49

Multiple antimicrobial resistance in plague: an emerging public health risk. PLoS One (2007) 4.21

Intensity of rainfall and severity of melioidosis, Australia. Emerg Infect Dis (2003) 3.41

Plague: past, present, and future. PLoS Med (2008) 3.23

Intraspecific diversity of Yersinia pestis. Clin Microbiol Rev (2004) 3.03

Syndromic surveillance and bioterrorism-related epidemics. Emerg Infect Dis (2003) 3.00

Small-molecule inhibitors specifically targeting type III secretion. Infect Immun (2005) 2.02

Resistance of Yersinia pestis to antimicrobial agents. Antimicrob Agents Chemother (2006) 1.97

Insight into microevolution of Yersinia pestis by clustered regularly interspaced short palindromic repeats. PLoS One (2008) 1.86

Epidemiologic determinants for modeling pneumonic plague outbreaks. Emerg Infect Dis (2004) 1.80

Current challenges in the development of vaccines for pneumonic plague. Expert Rev Vaccines (2008) 1.71

Current trends in plague research: from genomics to virulence. Clin Med Res (2006) 1.68

Characterization of phagosome trafficking and identification of PhoP-regulated genes important for survival of Yersinia pestis in macrophages. Infect Immun (2006) 1.66

Replication of Yersinia pestis in interferon gamma-activated macrophages requires ripA, a gene encoded in the pigmentation locus. Proc Natl Acad Sci U S A (2005) 1.64

A North American Yersinia pestis draft genome sequence: SNPs and phylogenetic analysis. PLoS One (2007) 1.63

Passive antibody administration (immediate immunity) as a specific defense against biological weapons. Emerg Infect Dis (2002) 1.51

Biological warfare at the 1346 siege of Caffa. Emerg Infect Dis (2002) 1.51

Gamma interferon, tumor necrosis factor alpha, and nitric oxide synthase 2, key elements of cellular immunity, perform critical protective functions during humoral defense against lethal pulmonary Yersinia pestis infection. Infect Immun (2006) 1.47

Enhanced drop-in syndromic surveillance in New York City following September 11, 2001. J Urban Health (2003) 1.45

Immune defense against pneumonic plague. Immunol Rev (2008) 1.44

Epizootiologic parameters for plague in Kazakhstan. Emerg Infect Dis (2006) 1.42

Temporal Progression of Pneumonic Plague in Blood of Nonhuman Primate: A Transcriptomic Analysis. PLoS One (2016) 1.39

The genome sequence of Yersinia pestis bacteriophage phiA1122 reveals an intimate history with the coliphage T3 and T7 genomes. J Bacteriol (2003) 1.36

Yersinia pestis caf1 variants and the limits of plague vaccine protection. Infect Immun (2008) 1.32

Identifying sources of human exposure to plague. J Clin Microbiol (2005) 1.32

Impact of resistance selection and mutant growth fitness on the relative efficacies of streptomycin and levofloxacin for plague therapy. Antimicrob Agents Chemother (2007) 1.28

Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells. Adv Drug Deliv Rev (2012) 1.25

Yersinia pestis evolution on a small timescale: comparison of whole genome sequences from North America. PLoS One (2007) 1.24

Braun lipoprotein (Lpp) contributes to virulence of yersiniae: potential role of Lpp in inducing bubonic and pneumonic plague. Infect Immun (2008) 1.24

Vaccination with live Yersinia pestis primes CD4 and CD8 T cells that synergistically protect against lethal pulmonary Y. pestis infection. Infect Immun (2006) 1.24

Biological warfare and bioterrorism. BMJ (2002) 1.23

Estimating the transmission potential of supercritical processes based on the final size distribution of minor outbreaks. J Theor Biol (2011) 1.22

Yersiniabactin iron uptake: mechanisms and role in Yersinia pestis pathogenesis. Microbes Infect (2011) 1.19

Effective plague vaccination via oral delivery of plant cells expressing F1-V antigens in chloroplasts. Infect Immun (2008) 1.18

Immunization with recombinant V10 protects cynomolgus macaques from lethal pneumonic plague. Infect Immun (2008) 1.18

Pneumonic plague cluster, Uganda, 2004. Emerg Infect Dis (2006) 1.15

The ABC transporter protein OppA provides protection against experimental Yersinia pestis infection. Infect Immun (2006) 1.14

The Yersinia pestis caf1M1A1 fimbrial capsule operon promotes transmission by flea bite in a mouse model of bubonic plague. Infect Immun (2008) 1.13

Plague: from natural disease to bioterrorism. Proc (Bayl Univ Med Cent) (2005) 1.12

Diagnostic bioluminescent phage for detection of Yersinia pestis. J Clin Microbiol (2009) 1.12

IL-17 contributes to cell-mediated defense against pulmonary Yersinia pestis infection. J Immunol (2010) 1.10

Development of vaccines against burkholderia pseudomallei. Front Microbiol (2011) 1.10

Broad T cell immunity to the LcrV virulence protein is induced by targeted delivery to DEC-205/CD205-positive mouse dendritic cells. Eur J Immunol (2008) 1.10

Yersinia pestis evades TLR4-dependent induction of IL-12(p40)2 by dendritic cells and subsequent cell migration. J Immunol (2008) 1.08

The smpB-ssrA mutant of Yersinia pestis functions as a live attenuated vaccine to protect mice against pulmonary plague infection. Infect Immun (2010) 1.07

Intraspecies and temperature-dependent variations in susceptibility of Yersinia pestis to the bactericidal action of serum and to polymyxin B. Infect Immun (2005) 1.07

Use of aminoglycosides in treatment of infections due to intracellular bacteria. Antimicrob Agents Chemother (2001) 1.07

Antibodies and cytokines independently protect against pneumonic plague. Vaccine (2008) 1.06

Small molecule inhibitors of LcrF, a Yersinia pseudotuberculosis transcription factor, attenuate virulence and limit infection in a murine pneumonia model. Infect Immun (2010) 1.06

Extensive antibody cross-reactivity among infectious gram-negative bacteria revealed by proteome microarray analysis. Mol Cell Proteomics (2008) 1.05

Immunization of mice with YscF provides protection from Yersinia pestis infections. BMC Microbiol (2005) 1.04

Proteomic characterization of Yersinia pestis virulence. J Bacteriol (2005) 1.04

Early host cell targets of Yersinia pestis during primary pneumonic plague. PLoS Pathog (2013) 1.04

TNFα and IFNγ contribute to F1/LcrV-targeted immune defense in mouse models of fully virulent pneumonic plague. Vaccine (2010) 1.04

Bacteriophage-resistant mutants in Yersinia pestis: identification of phage receptors and attenuation for mice. PLoS One (2011) 1.04

Development of an improved selective agar medium for isolation of Yersinia pestis. Appl Environ Microbiol (2003) 1.02

Transmission potential of primary pneumonic plague: time inhomogeneous evaluation based on historical documents of the transmission network. J Epidemiol Community Health (2006) 1.02

Direct transcriptional control of the plasminogen activator gene of Yersinia pestis by the cyclic AMP receptor protein. J Bacteriol (2007) 1.02

The role of relA and spoT in Yersinia pestis KIM5 pathogenicity. PLoS One (2009) 1.01

Global gene expression profiling of Yersinia pestis replicating inside macrophages reveals the roles of a putative stress-induced operon in regulating type III secretion and intracellular cell division. Infect Immun (2010) 1.01

Kinetics of innate immune response to Yersinia pestis after intradermal infection in a mouse model. Infect Immun (2012) 1.01

The NlpD lipoprotein is a novel Yersinia pestis virulence factor essential for the development of plague. PLoS One (2009) 1.01

Vaccination of mice with a Yop translocon complex elicits antibodies that are protective against infection with F1- Yersinia pestis. Infect Immun (2008) 1.00

Absence of inflammation and pneumonia during infection with nonpigmented Yersinia pestis reveals a new role for the pgm locus in pathogenesis. Infect Immun (2009) 1.00

Lessons learned about pneumonic plague diagnosis from two outbreaks, Democratic Republic of the Congo. Emerg Infect Dis (2011) 0.99

Protection Afforded by Fluoroquinolones in Animal Models of Respiratory Infections with Bacillus anthracis, Yersinia pestis, and Francisella tularensis. Open Microbiol J (2010) 0.98

Phage-based platforms for the clinical detection of human bacterial pathogens. Bacteriophage (2012) 0.98

Znu is the predominant zinc importer in Yersinia pestis during in vitro growth but is not essential for virulence. Infect Immun (2010) 0.98

Yersinia pestis with regulated delayed attenuation as a vaccine candidate to induce protective immunity against plague. Infect Immun (2010) 0.98

Milestones in progression of primary pneumonic plague in cynomolgus macaques. Infect Immun (2010) 0.97

Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection. Vaccine (2008) 0.97

D27-pLpxL, an avirulent strain of Yersinia pestis, primes T cells that protect against pneumonic plague. Infect Immun (2009) 0.96

Flea-borne transmission model to evaluate vaccine efficacy against naturally acquired bubonic plague. Infect Immun (2004) 0.96

Yersinia pestis YopE contains a dominant CD8 T cell epitope that confers protection in a mouse model of pneumonic plague. J Immunol (2011) 0.96

Liposome encapsulation of ciprofloxacin improves protection against highly virulent Francisella tularensis strain Schu S4. Antimicrob Agents Chemother (2014) 0.96

The resistance of BALB/cJ mice to Yersinia pestis maps to the major histocompatibility complex of chromosome 17. Infect Immun (2008) 0.95

Adenovirus-mediated delivery of an anti-V antigen monoclonal antibody protects mice against a lethal Yersinia pestis challenge. Infect Immun (2009) 0.94

In vitro efficacy of antibiotics commonly used to treat human plague against intracellular Yersinia pestis. Antimicrob Agents Chemother (2011) 0.94

Cethromycin-mediated protection against the plague pathogen Yersinia pestis in a rat model of infection and comparison with levofloxacin. Antimicrob Agents Chemother (2011) 0.94

Development and evaluation of two simple, rapid immunochromatographic tests for the detection of Yersinia pestis antibodies in humans and reservoirs. PLoS Negl Trop Dis (2009) 0.94

Innate immune response during Yersinia infection: critical modulation of cell death mechanisms through phagocyte activation. J Leukoc Biol (2009) 0.94

Prevention of immune cell apoptosis as potential therapeutic strategy for severe infections. Emerg Infect Dis (2007) 0.93

Purification and protective efficacy of monomeric and modified Yersinia pestis capsular F1-V antigen fusion proteins for vaccination against plague. Protein Expr Purif (2006) 0.93

Epidemiology of human plague in the United States, 1900-2012. Emerg Infect Dis (2015) 0.93

The Yersinia pestis chromosome encodes active addiction toxins. J Bacteriol (2010) 0.93

Levofloxacin cures experimental pneumonic plague in African green monkeys. PLoS Negl Trop Dis (2011) 0.92

Clinical and pathologic features of cynomolgus macaques (Macaca fascicularis) infected with aerosolized Yersinia pestis. Comp Med (2008) 0.92

Rapid and sensitive detection of Yersinia pestis using amplification of plague diagnostic bacteriophages monitored by real-time PCR. PLoS One (2010) 0.91

Discordance in the effects of Yersinia pestis on the dendritic cell functions manifested by induction of maturation and paralysis of migration. Infect Immun (2006) 0.91

YopH inhibits early pro-inflammatory cytokine responses during plague pneumonia. BMC Immunol (2010) 0.91

Fine-scale identification of the most likely source of a human plague infection. Emerg Infect Dis (2009) 0.91

Different pathologies but equal levels of responsiveness to the recombinant F1 and V antigen vaccine and ciprofloxacin in a murine model of plague caused by small- and large-particle aerosols. Infect Immun (2009) 0.89

Plague vaccines: current developments and future perspectives. Emerg Microbes Infect (2012) 0.89

Pulmonary Manifestations of Bioterrorism. Curr Infect Dis Rep (2001) 0.89

Modified caspase-3 assay indicates correlation of caspase-3 activity with immunity of nonhuman primates to Yersinia pestis infection. Clin Vaccine Immunol (2008) 0.89

The current state of bioterrorist attack surveillance and preparedness in the US. Risk Manag Healthc Policy (2014) 0.89

Characterization of an F1 deletion mutant of Yersinia pestis CO92, pathogenic role of F1 antigen in bubonic and pneumonic plague, and evaluation of sensitivity and specificity of F1 antigen capture-based dipsticks. J Clin Microbiol (2011) 0.89

Induction of pulmonary mucosal immune responses with a protein vaccine targeted to the DEC-205/CD205 receptor. Vaccine (2012) 0.88

Manganese transporters Yfe and MntH are Fur-regulated and important for the virulence of Yersinia pestis. Microbiology (2012) 0.88

Modulation of host immune defenses by Aeromonas and Yersinia species: convergence on toxins secreted by various secretion systems. Front Cell Infect Microbiol (2013) 0.88

Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med (1978) 14.65

Tularemia as a biological weapon: medical and public health management. JAMA (2001) 13.23

The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med (2001) 11.48

Homologous plant and bacterial proteins chaperone oligomeric protein assembly. Nature (1988) 9.55

Studies of cholera El Tor in the Philippines. I. Characteristics of cholera El Tor in Negros Occidental Province, November 1961 to September 1962. Bull World Health Organ (1965) 9.52

Botulinum toxin as a biological weapon: medical and public health management. JAMA (2001) 9.18

Susceptibility of anaerobes to cefoxitin and other cephalosporins. Antimicrob Agents Chemother (1975) 8.86

Anaerobic infections. 1. N Engl J Med (1974) 8.02

Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA (1999) 7.96

Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters. J Infect Dis (1977) 7.68

Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA (1999) 7.06

An enzymic site of inhibition of gibberellin biosynthesis by Amo 1618 and other plant growth retardants. Plant Physiol (1965) 7.03

Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite. N Engl J Med (2001) 6.76

Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA (2002) 6.59

Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey. Lancet (2001) 6.49

Controlled trial of three different antismoking interventions in general practice. Br Med J (Clin Res Ed) (1984) 6.25

Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992-1998. Investigation Team. N Engl J Med (1999) 6.20

Studies of cholera El Tor in the Philippines. 3. Transmission of infection among household contacts of cholera patients. Bull World Health Organ (1965) 6.17

Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Gastroenterology (1978) 5.91

Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process. J Biol Chem (1986) 5.86

A plaque reduction test for dengue virus neutralizing antibodies. J Immunol (1967) 5.78

Comparison of two toxins produced by Clostridium difficile. Infect Immun (1981) 5.16

Epidemiology and clonality of community-acquired methicillin-resistant Staphylococcus aureus in Minnesota, 1996-1998. Clin Infect Dis (2001) 5.07

Glanders in a military research microbiologist. N Engl J Med (2001) 4.77

Ethics and international research. BMJ (1997) 4.70

Clinical recognition and management of patients exposed to biological warfare agents. JAMA (1997) 4.67

An outbreak of primary pneumonic tularemia on Martha's Vineyard. N Engl J Med (2001) 4.60

Practice guidelines for the management of infectious diarrhea. Clin Infect Dis (2001) 4.49

Clostridium difficile colitis: an efficient clinical approach to diagnosis. Ann Intern Med (1995) 4.42

Studies of cholera El Tor in the Philippines. 2. A retrospective investigation of an explosive outbreak in Bacolod City and Talisay, November 1961. Bull World Health Organ (1965) 4.41

Cytotoxicity assay in antibiotic-associated colitis. J Infect Dis (1979) 4.39

Enzymes of the Glycolytic and Pentose Phosphate Pathways in Proplastids from the Developing Endosperm of Ricinus communis L. Plant Physiol (1977) 4.24

A national outbreak of Salmonella enteritidis infections from ice cream. The Investigation Team. N Engl J Med (1996) 4.14

The psychiatric status of patients with the chronic fatigue syndrome. Br J Psychiatry (1990) 4.10

Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations. Gastroenterology (1981) 4.04

Clindamycin-induced enterocolitis in hamsters as a model of pseudomembranous colitis in patients. Infect Immun (1978) 3.93

Weapons of mass destruction events with contaminated casualties: effective planning for health care facilities. JAMA (2000) 3.92

Experimental intra-abdominal abscesses in rats: development of an experimental model. Infect Immun (1974) 3.91

Studies of cholera El Tor in the Philippines. 4. Transmission of infection among neighbourhood and community contacts of cholera patients. Bull World Health Organ (1965) 3.90

Clinical and laboratory observations in Clostridium difficile colitis. Am J Clin Nutr (1980) 3.89

Infectious disease surveillance: a crumbling foundation. Science (1994) 3.89

An airborne outbreak of smallpox in a German hospital and its significance with respect to other recent outbreaks in Europe. Bull World Health Organ (1970) 3.88

Measles elimination in the Americas. Evolving strategies. JAMA (1996) 3.82

Quantitative bacteriology of the vaginal flora. J Infect Dis (1977) 3.81

A point-source outbreak of campylobacteriosis associated with consumption of raw milk. J Infect Dis (1985) 3.81

Principles of appropriate antibiotic use for acute pharyngitis in adults: background. Ann Intern Med (2001) 3.75

Smallpox and monkeypox in non-human primates. Bull World Health Organ (1968) 3.73

Management of anaerobic infections. Ann Intern Med (1975) 3.62

The capsular polysaccharide of Bacteroides fragilis as a virulence factor: comparison of the pathogenic potential of encapsulated and unencapsulated strains. J Infect Dis (1977) 3.62

Death due to bioterrorism-related inhalational anthrax: report of 2 patients. JAMA (2001) 3.55

Informed choice in genetic screening for thalassaemia during pregnancy: audit from a national confidential inquiry. BMJ (2000) 3.38

Rapid diagnosis of anaerobic infections by direct gas-liquid chromatography of clinical speciments. J Clin Invest (1976) 3.34